Liane Rae Teplitsky Buys 1,034 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky purchased 1,034 shares of the stock in a transaction on Friday, August 28th. The shares were purchased at an average price of $48.35 per share, with a total value of $49,993.90. Following the acquisition, the chief operating officer directly owned 2,070 shares in the company, valued at $100,084.50. This represents a 99.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Liane Rae Teplitsky also recently made the following trade(s):

• On Wednesday, August 26th, Liane Rae Teplitsky acquired 1,036 shares of Pulse Biosciences stock. The shares were acquired at an average cost of $48.23 per share, with a total value of $49,966.28.

Pulse Biosciences Stock Performance

PLSE opened at $47.57 on Friday. Pulse Biosciences, Inc has a one year low of $12.56 and a one year high of $50.90. The company has a market cap of $3.29 billion, a P/E ratio of -40.31 and a beta of 1.61. The business’s 50-day simple moving average is $35.38 and its 200-day simple moving average is $27.00.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. As a group, analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pulse Biosciences

A number of large investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in shares of Pulse Biosciences in the first quarter valued at approximately $323,000. Creative Planning lifted its holdings in Pulse Biosciences by 26.3% in the second quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after acquiring an additional 3,951 shares during the period. Legal & General Group Plc boosted its position in shares of Pulse Biosciences by 57.7% during the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock worth $338,000 after purchasing an additional 8,197 shares in the last quarter. Norges Bank acquired a new position in shares of Pulse Biosciences during the 2nd quarter worth $302,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $158,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on PLSE shares. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Needham & Company LLC assumed coverage on Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 target price for the company. Canaccord Genuity Group raised their price target on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Finally, Mizuho set a $45.00 target price on shares of Pulse Biosciences in a research report on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.